Some Payers Make Exceptions for Earlier CAR-T Dosing
-
Feb 13, 2025
Cellular therapies made meaningful achievements in 2024, with two of them involving a pair of chimeric antigen receptor T cell (CAR-T) therapies that gained FDA approval for use in earlier lines of setting for the treatment of relapsed or refractory multiple myeloma (RRMM). According to a recent survey, some payers already have been making exceptions to allow for earlier use of CAR-Ts than what is indicated on their labels.
On April 4, 2024, the FDA approved Abecma (idecabtagene vicleucel) from Bristol Myers Squibb and 2seventy bio, Inc. for the treatment of adults with triple-class exposed RRMM after at least two lines of therapy. The following day, the FDA approved Carvykti (ciltacabtagene autoleucel) from the Janssen Pharmaceutical Companies of Johnson & Johnson and Legend Biotech USA, Inc. for the treatment of adults with RRMM who have received at least one prior line of therapy. Both agents had previously been approved for the treatment of RRMM after at least four lines of therapy.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.